Prasugrel 5 mg in LBW patients reduced platelet reactivity to a similar extent as prasugrel 10 mg in HBW patients and resulted in greater platelet inhibition.
Missing: Pharmacokinetics pharmacodynamics
People also ask
What are the pharmacokinetics of prasugrel?
What is the expected pharmacological action of prasugrel?
What does prasugrel do to the body?
Why is prasugrel discontinued?
Apr 10, 2023 · Prasugrel 5 mg in low body weight (< 60 kg) individuals reduced platelet reactivity similarly to 10 mg in higher body weight individuals (> 60 ...
Prasugrel 5 mg in LBW patients reduced platelet reactivity to a similar extent as prasugrel 10 mg in HBW patients and resulted in greater platelet inhibition, ...
Prasugrel 5 mg in LBW patients reduced platelet reactivity to a similar extent as prasugrel 10 mg in HBW patients and resulted in greater platelet inhibition.
After administration, 5 mg and higher dose groups showed a tendency for prolonged bleeding time. The peak level of bleeding time of 5 mg, 7.5 mg, and 10 mg ...
Jul 27, 2010 · In both clinical pharmacology studies and TRITON–TIMI 38, prasugrel pharmacokinetics were affected by body weight, with higher exposure in ...
Oct 16, 2013 · Baseline MPA was similar between patients in the low and high body weight groups. (Figure 3). The comparison for non-inferiority was done ...
... 10-mg MD in subjects with higher body weight. This study will provide further support for the prasugrel 5-mg MD recommendation in subjects <60 kg in weight.
PRASUGREL 5 MG IN LOW BODY WEIGHT PATIENTS REDUCES PLATELET REACTIVITY TO A SIMILAR EXTENT AS PRASUGREL 10 MG IN HIGHER BODY WEIGHT PATIENTS: RESULTS FROM THE ...
Oct 22, 2012 · Aim: To characterize the pharmacokinetics (PKs), pharmacodynamics (PDs), and tolerability of different dose regimens of prasugrel in healthy ...
